Back to results
US 9,750,726 B2Granted
Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
AssigneeGlaxo Group Limited
InventorsDarrell Baker, Mark Bruce, Glenn Crater, Brian Noga, Marian Thomas, Patrick Wire
Life of this patent
Estimating the term…
Abstract
Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
Claims17
A pharmaceutical combination product comprising:
- a) 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide in an amount of about 62.5 mcg/dose, in the form of a dry powder;
- and
- b) 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate, in an amount of about 25 mcg/dose, in the form of a dry powder,
- wherein said pharmaceutical combination product is suitable for once-daily administration, and compounds a) and b) are presented in a form adapted for simultaneous administration.
1 more element
A pharmaceutical combination product comprising:
- a) a first dry powder composition comprising 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide, in an amount of about 62.5 mcg/dose;
- lactose;
- and magnesium stearate in an amount of about 0.6% w/w of said first dry powder composition;
- and
- b) a second dry powder composition comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate, in an amount of about 25 mcg/dose;
- lactose, and;
- magnesium stearate in an amount of about 1.0% w/w of said second dry powder composition;
- wherein said pharmaceutical combination product is suitable for once-daily administration, and
- wherein the first and second dry powder compositions are configured for simultaneous administration.
6 more elements
A pharmaceutical combination product comprising:
- a) 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide in an amount of 62.5 mcg/dose, in the form of a dry powder;
- b) 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate, in an amount of 25 mcg/dose, in the form of a dry powder,
- c) 6α,9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid S-fluoromethyl ester (fluticasone furoate), in an amount of 100 mcg/dose, in the form of a dry powder,
- d) carrier excipient, and
- e) ternary agent, wherein said pharmaceutical combination product is suitable for once-daily administration, and compounds a), b) and c) are presented in a form adapted for simultaneous administration.
2 more elements
Dependencies are inferred from the claim text.